Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas-Reference-Cited by-同舟云学术

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas

Published:2018-01 Issue:1 Volume:18 Page:58-64
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Puvvada Soham D.,Guillen-Rodriguez José,Kumar Abhijeet,Inclán Lora,Heard Kara,Rivera Xavier I.,Anwer Faiz^ORCID,Schatz Jonathan H.^ORCID,Mahadevan Daruka,Persky Daniel O.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference37 articles.

1. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004;Zhou;Cancer,2008

2. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma. SWOG 0213;Bernstein;Ann Oncol,2013

3. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte;Delarue;Blood,2013

4. Progress and promise in the treatment of indolent lymphomas;McLaughlin;Oncologist,2002

5. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma;Fisher;J Clin Oncol,2006

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Elderly Patients with Mantle Cell Lymphoma;2024-03-27

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib;Acta Pharmacologica Sinica;2021-04-13

5. Management of Drug Resistance in Mantle Cell Lymphoma;Cancers;2020-06-12